Facio successfully completes first equity round with close to €2.5M in total proceeds


Leiden, the Netherlands - October 2, 2015

Facio Therapies has obtained close to €500,000 in equity funding from the FSHD Global Research Foundation as well as private investors from both within and outside the FSHD community. These funds are in addition to the €2 million equity financing raised in 2014. Facio will use the financing proceeds to identify compounds that show potential… read more

Facio enters into agreement with scientific leaders to advance its drug discovery program


Leiden, the Netherlands - June 23, 2015

Leading academic institutes active in the field of FSHD have agreed to transfer materials to Facio for its drug discovery program aimed at stopping the progression of FSHD.  Facio’s drug discovery program is designed to identify compounds showing activity as a potential treatment to stop the progression of FSHD. The Dutch based Leiden University Medical… read more

Facio partners with Evotec and initiates FSHD drug discovery program


Leiden, the Netherlands - April 29, 2015

Facio Therapies and Evotec have entered into an agreement aimed at the identification of compounds showing activity as a potential treatment to stop the progression of FSHD. This agreement marks the start of finding a drug to overcome FSHD. Facio’s drug discovery program aims to identify compounds that increase the activity of SMCHD1 and restore the repression of… read more

Facio congratulates Bill Moss AO


Leiden, the Netherlands - January 28, 2015

Facio’s founding father and investor Bill Moss AO has been appointed Officer of the Order of Australia. He has succeeded in putting FSHD on the map and is dedicated to finding a treatment and cure for FSHD. David Dasberg, Managing Director of Facio: “We congratulate Bill with this recognition. We are very proud to have him on board… read more

Facio reinforces team


Leiden, the Netherlands - January 16, 2015

Facio Therapies has retained Joris De Maeyer and Lars Bastiaanse to support its drug discovery and development program aimed at stopping the progression of FSHD. Joris is responsible for drug discovery and early development, while Lars is responsible for Facio’s overall drug development strategy.  Joris De Maeyer is seconded to Facio from DM&S consulting (Mechelen, Belgium)… read more